Summary: (D-ala 2 )-met5-encephalinamide (AM encepha linamide) and (D-ala 2 )-leu5-encephalinamide (AL enceph alinamide) were administered into the cisterna magna in anesthetized dogs to determine whether these opiates ef fected the neurohypophyseal circulation differently than the circulation of other brain areas. At the beginning of the experimental protocol, animals were given either mock cerebral spinal fluid (CSF) or 5 or 25 mg of AM encephalinamide or 5 mg of AL encephalinamide in equal volumes of mock CSF into the cisterna magna. By 60 min after intracisternal injection. radiolabeled AM encepha linamide distributed throughout the brain with the highest concentration being in the area of the brainstem. Sixty minutes after intracisternal injection, heart rate was de creased 29.0 ± 5.1%, 41.3 ± 4.4%, and 36.0 ± 3.6%, and MABP was decreased 25.2 ± 8.0%, 26.4 ± 2.4%, and 32.3 ± 2.6% in animals treated with AL encephalin amide (5 mg), AM encephalinamide (5 mg), and AM en cephalinamide (25 mg), respectively. Neither AL ence phalinamide or AM encephalinamide altered CBF or CMR0 2 when compared with animals treated with mock CSF, whereas both AL encephalinamide and AM ence phalinamide reduced neurohypophyseal blood flow by 30
leucine-encephalin, respectively, and have potent long-lasting opiate-like activity (Pert et aI., 1976) .
Several investigators have evaluated the effects of opiates on the cerebral circulation. Hanko and Hardebo (1978) demonstrated that methionine-en cephalin and leucine-encephalin are capable of causing a naloxone-reversible dilation of actively contracted feline middle cerebral arteries in vitro. Wahl (1985) showed that AM encephalinamide and AL encephalinamide produced a moderate vasodi lation of feline pial arteries when given in pharma cologic concentrations but had no effect when given in physiologic concentrations. Studies in vivo of these agents may be complicated by the hypo tensive effects of opiate receptor agonists and by the systemic release of histamine that occurs with some narcotics (Thompson and Walton, 1964) . It is, therefore, not surprising that opiate receptor ago nists have been shown to either decrease or not change cerebral blood flow and metabolism (Carlsson et aI., 1982; McPherson and Traystman, 1984) . For example, local application of methio nine-encephalin to the cerebral cortex in awake, freely moving cats caused a marked reduction in CBF (Sandor et aI., 1983) , but systemic administra tion of (D-met 2 , pro5)-encephalinamide caused dila tation of pial arteries (Kobari et aI., 1985) with no change in CBF (Sandor et aI., 1986b) . It is likely that the pial artery dilation with systemic opiate ad ministration is related to autoregulation in response to arterial hypotension.
The role that opiates play in neurohypophyseal function has been studied widely yet the results are conflicting. Opiates have been shown to both stim ulate (Bissett et aI., 1978) and depress (Van Wi mersma Greidanus et aI., 1979) arginine vaso pressin release by the neurohypophysis. That opiates may be important modulators of neurohy pophyseal blood flow has not been previously in vestigated. In this study, we tested the hypothesis that intracisternally administered opiates rapidly distribute throughout the brain to cause changes in blood flow and function of the neurohypophysis while not affecting total brain oxygen consumption or blood flow.
MATERIALS AND METHODS

General preparation
Adult mongrel dogs of either sex (18-25 kg) were anes thetized with sodium pentobarbital (30 mg/kd, i.v.) and maintained with intermittent pentobarbital supplements as needed to suppress the pedal pain reflex. Each dog was mechanically ventilated (Harvard Respirator Model 607 South Natick, MA, U.S.A.) so that minute ventila tion could be adjusted to maintain arterial Peo 2 between 35 and 40 torr throughout the experiment. Supplemental J Cereb Blood Flow Metab, Vol. 8, No.3, 1988 oxygen was administered as needed to maintain arterial P0 2 above 80 torr. Rectal temperature was maintained at 38 ± 0.5°C with the use of heat lamps and a heating pad.
A catheter was placed in a femoral vein and advanced into the inferior vena cava for administration of fluids and drugs. MABP was monitored via a catheter inserted into the descending aorta via a femoral artery. A left ventric ular catheter (7-French, cardiac catheter) was placed via the other femoral artery for injection of radiolabeled mi crospheres. Left ventricular pressure was continuously monitored throughout the experiment to insure that the catheter remained in the left ventricle, and catheter placement was also confirmed at autopsy. A catheter placed in the subclavian artery via the brachial artery was used to obtain the reference withdrawal sample during the microsphere injection. After insertion of all catheters, the dog was turned prone, and its head was stabilized so that the external auditory meatus was approximately 10 cm above the level of the heart. The superior sagittal sinus was exposed approximately 1 cm cephalad to the confluence of the sinuses and cannulated anteriorly. The catheter was used to collect cerebral venous blood samples for gas analysis. A 22-gauge, I-in angiocatheter was inserted under direct vision into the cisterna magna through the atlanto-occipital membrane. This catheter was used for measuring cerebrospinal fluid pressure (Pcsf) and for the administration of drugs.
Arterial, left ventricular, and sagittal sinus blood pres sures and Pcsf were measured continuously with Statham P-23 pressure transducers and recorded on a Gould Brush recorder (Cleveland, OH, U.S.A.). Heart rate was determined electronically from the electrocardiogram. Arterial and sagittal sinus Po 2 , Pe0 2 , and pH were mea sured with Radiometer BMS3 electrodes and analyzer (Copenhagen, Denmark). Oxygen content and saturation were determined with a CO-oximeter (Instrumentation Laboratory model 282 Lexington, MA, U.S.A.). The blood gas analyzer and CO-oximeter were calibrated be fore and after each blood sample analysis. The BMS-3 electrodes were calibrated with air and mixtures of O 2 in N 2 (8%) and CO 2 in air (5 and 10% CO 2 ) to a precision of 0.1 %. The pH electrode was calibrated with standard phosphate buffers (6.840; 7.381).
Cerebral blood flow. Regional cerebral blood flow was measured using the reference sample radio labeled mi crosphere technique (Rudolph and Heymann, 1972) . Briefly, 15 ± 1.5-J.Lm diameter micro spheres were in jected into the left ventricle and a reference sample was withdrawn with a Harvard pump from the catheter in the subclavian artery. Prior to injection, the microspheres were agitated in an ultrasonic mixer for at least 20 min and vigorously shaken with a vortex mixer. For each flow measurement, approximately 4 x 106 spheres were in jected into the left ventricular catheter and flushed with 20 cc of normal saline over a period of 20 s. The six isotopes used (153Gd, 51Cr, 113Sn, 46SC, 95Nb, and J03Ru) in each dog were injected in random sequence. The number of microspheres injected in each dog was chosen to allow at least 400 spheres to be delivered to the smallest tissue sample taken. The reference sample was withdrawn at 3.82 mllmin beginning just prior to microsphere injection and continued for 2 min after completing the infusion of the flush solution. The microsphere injection did not alter arterial blood pressure.
At the end of each experiment, the dog was killed with KCl and the tissues were removed for processing. The brain was placed into 10% buffered formalin for 2-10 days prior to sectioning. The brain was sectioned in order to determine blood flow to the following areas: caudate nucleus, hippocampus, hypothalamus, thalamus, cere bellum, midbrain, pons, medulla, neurohypophysis, and whole brain. After sectioning, each tissue sample was weighed and placed into 15-ml poly Q vials for analysis in an autogamma scintillation spectrometer (Packard Model 9042 Downers Grove, IL, U.S.A.) with a 3-in through hole N al crystal. The energy windows were set at 70-174 KeV for l53Gd, 220-364 KeV for 51Cr, 370-440 KeV for I13Sn, 460-550 KeV for 103Ru, 710-800 KeV for 95Nb, and 840-1,200 KeV for 46SC• The overlap of activity from high-energy isotopes into low-energy windows was stripped to obtain corrected counts for each isotope (CT).
Blood flow to each brain region was calculated from the formula Ch = CT x QR/C" where QT is the flow to the tissue; Cr is the corrected counts per minute in the tissue sample; QR is the reference flow rate; and Cr is the cor rected counts per minute in the reference sample. Flows are expressed in milliliters per minutes per 100 g of tissue by normalizing for tissue weight. CMR0 2 was calculated from the formula CMR0 2 = (A -V) CBF where A and V are the arterial and cerebral venous oxygen content, respectively, and CBF is total cerebral blood flow. CMR0 2 is expressed as milliliters of oxygen per minute per 100 g of tissue by normalizing for tissue weight.
Protocols
Cerebrovascular effects of encephalinamide. Tw enty five dogs were each given one of four different drug treat ments. In each group, measurements of CBF and blood gases were made prior to drug injection (at least 30 min after the end of surgery and after the last dose of pento barbital) and then 5, 15, 30, and 60 min after intracisternal administration of the drug, diluted in 0.2 ml mock CSF (Levasseur et aI., 1975) . The drug treatments were as follows: mock CSF time controls (n = 5); 5 mg AM en cephalinamide (n = 7); 25 mg AM encephalinamide (n = 8); and 5 mg AL encephalinamide (n = 5). The dose of each drug was chosen to produce cardiovascular evi dence of drug penetration in brain parenchyma (Laubie et aI., 1977) so that the time course of the effects of the drug could be determined. After drug injection, the cisternal catheter was flushed with 0.4 ml of mock CSF in all four groups. At the end of the 60-min protocol, naloxone was administered i.v. to reverse the effects of the centrally administered opiates. Five minutes following naloxone administration, CBF and blood gas measurements were made. The dose of naloxone was administered in either of two dose levels: 0.8 mg/dog (-0.04 mg/kg; low dose) or 100 mg/dog (-5 mg/kg; high dose).
Distribution of radiolabeled intracisternal encephalin amide. In four dogs, the brain distribution of intracister nally administered AM encephalinamide was determined: 0.4 nmol of 1 2 51-labeled AM encephalinamide (2,200 Ci/ mmol NEN, Boston, MA) dissolved in 0.2 ml of mock CSF was injected into the cisternal catheter. After the catheter was flushed with 0.4 ml of mock CSF, 1 2 51_AM encephalinamide was allowed to diffuse through the CSF space for 60 min. Sixty minutes was chosen because this was the last time point used in the other protocol. Arte rial blood gases were measured at 20-min intervals throughout this period, and arterial pressure and Pcsf were recorded. The dog was then killed with KCI and the brain removed for sectioning into the following areas: neurohypophysis, adenohypophysis, hypothalamus, thal amus, surface of medulla, deep medulla, surface of pons, deep pons, surface of midbrain, deep midbrain, cere bellum, caudate nucleus, surface of the frontal lobe, deep frontal lobe, surface of parietal lobe, deep parietal lobe, surface of occipital lobe, and deep occipital lobe. Each of the surface sections were approximately 1 mm in thick ness. The samples were then counted in an autogamma scintillation spectrometer. Tissue counts were normal ized for tissue weight and then expressed as a percentage of the activity in the medulla surface section (i.e., the section with the highest activity).
Arginine vasopressin assay
Plasma arginine vasopressin was measured in four of five dogs treated with mock CSF, four of five dogs treated with AL en cephalin amide (5 mg), three of seven dogs treated with AM encephalinamide ( 5 mg) and seven of eight dogs treated with AM encephalinamide (25 mg) at the same time points that CBF and CMR0 2 were deter mined. A commercially available radioimmunoassay (Im muno Nuclear Corp., Stillwater, MN, U.S.A.) was used to measure plasma arginine vasopressin concentration. Seven-milliliter aliquots of arterial blood were collected in EDTA tubes and quickly centrifuged. The plasma was separated and frozen at -70°C. Plasma extraction was performed on ODS (SEP-PAK) columns with a 10% acetic acid wash. Arginine vasopressin was eluted from the column with a methanol wash. The methanol was then evaporated and the unknowns resuspended in an ap propriate amount of bovine serum albumin. The assay was performed by incubating the unknowns in the pres ence of sequentially added 1 2 51 arginine vasopressin, guinea pig antivasopressin antibody, and rabbit anti guinea pig precipitating complex. The radioactive precip itate was then counted using a 2-88-KeV window. Con centrations were determined from a standard curve cov ering the range of arginine vasopressin concentration from 5 to 80 pg/ml (Peninsula Laboratory, Belmont, CA). The sensitivity of the assay is 2.5 pg/ml, and the antibody shows < 0.01 % cross-reactivity with oxytocin and 0.14% cross-reactivity with vasotocin. Recovery studies show 84% recovery over the range of 3-90 pg/ml.
Statistical analysis
All values are reported as the mean ± one SEM. Anal ysis of variance (ANOVA) was used to compare blood flow and other physiologic parameters during the 60-min protocol. The level of significance was set at p < 0.05. Dunnett's test was then applied to all tests yielding signif icant differences (p < 0.05). Singular comparisons, such as differences between blood flows measured after i.v. naloxone administration and values obtained 60 min after opiate administration, were made by the paired Student t test. The Student t test was also used to determine differ ences from animals treated with artificial CSF. In the 1 2 51 _ AM encephalinamide studies, surface section counts were compared with deep sections with the paired t test.
Results
Infusing mock CSF, AL encephalinamide, or AM encephalinamide into the cisterna magna was not associated with any physiologically significant change in blood gas data (Table O . As expected, 
Key: all values are mean ± SEM; mock CSF (n = 5); ALE, 5 mg (n = 5); AME, 5 mg (n = 7); AME, 25 mg (n = 8); Pcsf, cisterna magna pressure; ALE (n-ala 2 )-met5-encephalinamide; AME (n-ala 2 )-met5-encephalinamide; Po 2 , arterial blood partial pressure of oxygen; Pco 2 , arterial blood partial pressure of carbon dioxide; HR, heart rate. a p < 0.05 as compared with pre injection control values.
b p < 0.05 as compared with 60-min time point value.
there was a small increase in Pcsf and a decrease in heart rate in animals treated with either AM en cephalinamide or AL encephalinamide (Table O. The largest reduction in heart rate was recorded 60 min after injection in all groups and averaged 29. 0 ± 5. 1%, 41.3 ± 4.4%, and 36.0% ± 3.6% for all animals treated with AL encephalinamide (5 mg), AM encephalinamide (5 mg), and AM enceph alinamide (25 mg), respectively ( minutes after intracisternal injection, MABP also fell by 25.2 ± 8. 0%,26.4 ± 2.4%, and 32.3 ± 2. 6% as compared with the pre injection value in animals treated with AL encephalinamide, AM encephalin amide (5 mg), and AM encephalinamide (25 mg), respectively ( Fig. 1) . At the same time point, cere bral vascular resistance was decreased by 34 ± 6%, 27 ± 6%, and 32 ± 3% in animals treated with AL encephalinamide, AM encephalinamide (5 mg), Table 2 shows the effect of intracisternal AM en cephalinamide and AL encephalinamide on re gional CBF. As compared with animals given mock CSF, animals given encephalinamide showed a transient increase in blood flow to the hippocampus and a sustained decrease in flow to the neurohy pophysis but no alteration in flow to the other organ regions tested. During the control period, blood flow to the neurohypophysis was comparable with that reported in other studies (Page et al. , 198 1; Wilson et al. , 1985) . Blood flow to the neuro hypophysis (Fig. 2) was markedly reduced by AM encephalinamide and AL encephalinamide when compared with blood flow of animals given mock CSF. Blood flow to the neurohypophysis was re duced at 30 (43 ± 11%) and 60 (34 ± 10%) min after injection of AL encephalinamide, at 30 (35 ± 7%) and 60 (37 ± 3%) min after injection of AM encephalinamide (5 mg), and at 30 (46 ± 8%) and 60 (38 ± 4%) min after injection of AM encephalin amide (25 mg) (Fig. 2) . Plasma arginine vasopressin levels were unchanged for the duration of the ex periment in animals treated with mock CSF or AM encephalinamide (5 mg). Plasma arginine vaso pressin levels were elevated at 15 (326 ± 75% AL encephalinamide; 323 ± 109% AM encephalina mide, 25 mg) and 30 min (27 1 ± 68% AL encepha linamide; 368 ± 136% AM encephalinamide, 25 mg) after intracisternal injection (Fig. 2) .
At the end of the 60-min protocol, i. v. naloxone had no effect on plasma arginine vasopressin levels. In animals treated with mock CSF, i.v. naloxone was also not associated with any alterations in blood flow or hemodynamic values. In animals treated with AL encephalinamide, i. v. naloxone (0.8 mg/dog) was associated with an increase in heart rate (104 ± 14 to 113 ± 13 beats/min) and MABP (102 ± 11 to 116 ± 11 mm Hg) (Fig. 3 ) but no change in regional blood flows. In animals treated with AM encephalinamide (5 mg), naloxone (0.8 mg/dog) was associated with an increased heart rate (79 ± 9 to 132 ± 12 beats/min), MABP (109 ± 2 to 135 ± 4 mm Hg), and blood flow to the neuro hypophysis (242. 4 ± 40. 4 to 368.8 ± 62. 6 mllmin/ 100 g). Even though overall CBF was not altered by AM encephalinamide (5 mg), naloxone administra tion increased overall CBF (28.4 ± 3 to 31.5 ± 3. 5 mllmin/l00 g) (Fig. 3) . Blood flow to other brain re gions was not affected by naloxone administration (Table 2) . Naloxone (100 mg/dog) increased heart rate (96 ± 6 to 128 ± 7 beats/min), MABP (87 ± 7 to 146 ± 16 mm Hg), and blood flow to the neuro hypophysis, midbrain, caudate nucleus, and whole brain in animals with AM encephalinamide (25 mg) (Table 2; Figure 3 ).
To ascertain whether the different regional effects of AL encephalinamide and AM encephalinamide on regional blood flow were related to a differential distribution of the encephalinamides, we measured relative regional concentrations of 1 2 5I_AM enceph alinamide in the brain after administration into the cisterna magna. 1 2 5I_AM encephalinamide adminis tration caused no changes in Pcsf, MABP, or arte rial blood gases data from control values of 9.5 ± 1 mm Hg (Pcs£); 15 1 ± 9 mm Hg (MABP); 123 ± 10 mm Hg (Po 2 ); 36 ± 2 mm Hg (Pco 2 ); 7. 39 ± 0. 02 (pH). Sixty minutes after intracisternal injection of 1 2 5I_AM encephalinamide, the highest concentra tion of radioactivity was found in the medulla sur face section and averaged 2,96 1, 111 ± 305,265 counts/min/g wet weight. We have expressed the activity to other areas of the brain as a percentage of the activity in the medulla surface section for each animal so that the degree of spread could easily be determined (Fig. 4) . In the medulla, pons, midbrain, and frontal lobe, there was significantly more activity in the surface sections as compared with the deep sections (paired t test). The activity in the neurohypophysis was 11.0 ± 2. 1% of the ac tivity in the medulla surface section.
DISCUSSION
Neither AM encephalinamide nor AL encepha linamide altered total CBF or CMR0 2 when admin- istered into the cisterna magna. However, these opiates caused both a reduction in neurohypophy seal blood flow that could be antagonized by i. v. naloxone and an attenuation of the arginine vaso pressin response that normally occurs with sys temic hypotension. We believe that this reduction in blood flow to the neurohypophysis may be me diated through opiate receptor activation.
Opiate receptors that react with enkephalins have been identified throughout the neuroaxis (Goodman, 1980) and in association with intracere bral microvessels (Peroutka et aI., 1980) . Likewise, met-encephalin-like immunoactive profiles have been demonstrated in close proximity to cerebral arterioles (Kapadia and deLanerolle, 1984) . We therefore hypothesized that stimulation of these re ceptors with opiate agonists may result in a general ized effect on CBF. Our data support that of other laboratories using encephalinamides as opiate ago nists and suggest that the opiates do not play a di rect role in the regulation of total CBF (Wahl, 1985; Sandor et aI., 1986b ).
An alternative explanation for the lack of an ef· fect on overall CBF could be that we did not supply an adequate amount of opiate to the receptor site. Rennels et ai. (1985) have shown that intracister nally administered agents rapidly distribute throughout the neuroaxis. Likewise, our 1 2 5I-AM encephalinamide-distribution study suggests that intracisternal administration of 5-25 mg encepha linamide should produce drug levels of 10-3 Min the brainstem and 10-4 M elsewhere throughout the brain, including the neurohypophysis. These levels far exceed those that would be expected to cause an effect on CBF if opiate control of CBF was of physiologic significance (Wahl, 1985) . In deed, these levels markedly affected blood flow to the neurohypophysis but not to other brain areas. The overall blood flow response is not altered by using different agonists (i.e. , AL encephalinamide, AM encephalinamide, and D-met 2 , pro5-encephalin amide), by increasing the amount of agonist admin istered (5-25 mg), or by changing the site of admin istration (intracisternal versus systemic) (Sandor et ai. , 1986b) in spite of consistent cardiovascular evi dence for opiate penetration into brain parenchyma (Laubie et ai., 1977; Punnen et ai. , 1984) . We concur with Wahl (1985) that the opiate-in duced decrease in CBF reported by others may be secondary to an opiate-induced decrease in cere bral metabolism in lightly anesthetized animals (Carlsson et ai., 1982) and not an effect of direct stimulation on vascular opiate receptors. If the opiates were direct cerebral vasoconstrictors, their administration would be associated with a decrease in CBF in spite of an already reduced cerebral me tabolism, as found in well-anesthetized animals. In the current study, and in other studies of opiates in fully anesthetized animals, opiates did not decrease CBF and therefore are not direct cerebral vasocon strictors (McPherson and Traystman, 1984; Sandor et ai., 1986b) . We can not exclude the possibility that, although we did not see an effect in dogs, and Sandor et ai. (1986b) did not see one in cats, opiates J Cereb Blood Flow Metab, Vol. 8, No. 3, 1988 may be important in the regulation of CBF in other species. Indeed, in the rat, opiates appear to be im portant in the regulation of blood flow to the hypo thalamus (Sandor et aI., 1986a; Sandor et aI. , 1986c) .
The effect of opiates on the neurohypophysis was quite distinct from the effects elsewhere in the brain despite the ability to obtain higher concentra tions of opiates elsewhere. There are several poten tial mechanisms for the observed reduction in neur ohypophyseal blood flow. We believe that the re duction of neurohypophyseal blood flow is due to direct stimulation of opiate receptors on the neuro hypophyseal vasculature. It is unlikely that the re duction in blood flow is a passive response of the vasculature to the decrease in MABP that occurred with intracisternal opiate administration; equal re ductions in blood pressure normally are associated with a marked initial increase in neurohypophyseal blood flow (Wilson et ai., 1985) followed by a re turn to control values (Page et ai. , 198 1) . The de crease in blood flow to the neurohypophysis could also be secondary to a primary effect of the opiates on neurohypophyseal parenchyma. Indeed, AM encephalinamide and AL encephalinamide both caused an attenuation of arginine vasopressin re lease in response to hypotension (Wilson et aI., 1985) . However, we suggest that the neurohypo physeal blood flow reduction was due to a predomi nant effect on neurohypophyseal vessels since i. v. naloxone at the end of the protocol increased neurohypophyseal blood flow in animals with AM encephalinamide without altering plasma arginine vasopressin levels. The neurohypophysis is believed to be populated by )J.--1 receptors, which are inhibitory and nal oxone-sensitive, and )J.--2 receptors, which are stim ulatory and naloxone-insensitive (Kamoi and Rob ertson, 1985) . It is not known which, if either, of these receptors exists on blood vessels of the neu rohypophysis. It must also be pointed out that poly synaptic pathways may be of importance in the current study as neuronal projections have been demonstrated between the brainstem (in close proximity to where the opiates were administered) and arginine vasopressin-containing neurons of the supraoptic nucleus and paraventricular nucleus (Dahlstrom and Fuxe, 1965) . Direct application of opiates to the fourth ventricular region may have been a contributing factor to our results by acti vating or depressing such polysynaptic pathways.
In summary, opiates are potent modulators of neurohypophyseal function and blood flow, yet they do not appear to be important in the control of blood flow to other brain regions.
